CWA Asset Management Group LLC Sells 2,963 Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

CWA Asset Management Group LLC cut its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 11.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 23,642 shares of the specialty pharmaceutical company's stock after selling 2,963 shares during the quarter. CWA Asset Management Group LLC's holdings in Jazz Pharmaceuticals were worth $2,935,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. LSV Asset Management grew its holdings in shares of Jazz Pharmaceuticals by 1.5% during the fourth quarter. LSV Asset Management now owns 2,531,050 shares of the specialty pharmaceutical company's stock valued at $311,699,000 after purchasing an additional 37,108 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in Jazz Pharmaceuticals by 18.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company's stock worth $250,619,000 after buying an additional 320,724 shares in the last quarter. Capital World Investors grew its holdings in Jazz Pharmaceuticals by 5.7% in the 4th quarter. Capital World Investors now owns 1,923,342 shares of the specialty pharmaceutical company's stock worth $236,860,000 after buying an additional 104,195 shares in the last quarter. Ameriprise Financial Inc. grew its holdings in Jazz Pharmaceuticals by 20.9% in the 4th quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company's stock worth $225,076,000 after buying an additional 315,608 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in Jazz Pharmaceuticals by 4.8% in the 4th quarter. JPMorgan Chase & Co. now owns 1,587,541 shares of the specialty pharmaceutical company's stock worth $195,506,000 after buying an additional 72,007 shares in the last quarter. 89.14% of the stock is owned by institutional investors.

Jazz Pharmaceuticals Stock Down 0.7%

Jazz Pharmaceuticals stock traded down $0.73 during mid-day trading on Friday, hitting $107.51. 1,053,788 shares of the company's stock were exchanged, compared to its average volume of 827,456. The company has a current ratio of 3.38, a quick ratio of 2.97 and a debt-to-equity ratio of 1.28. The stock has a market cap of $6.51 billion, a P/E ratio of 14.33, a P/E/G ratio of 4.64 and a beta of 0.33. Jazz Pharmaceuticals PLC has a 1-year low of $95.49 and a 1-year high of $148.06. The stock has a 50 day moving average of $108.14 and a two-hundred day moving average of $120.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 EPS for the quarter, missing the consensus estimate of $4.65 by ($2.97). The business had revenue of $897.84 million for the quarter, compared to analyst estimates of $984.16 million. Jazz Pharmaceuticals had a return on equity of 26.62% and a net margin of 11.86%. The company's quarterly revenue was down .5% compared to the same quarter last year. During the same period in the previous year, the company earned $2.68 earnings per share. As a group, analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the company's stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $123.75, for a total transaction of $185,625.00. Following the completion of the sale, the chief executive officer now directly owns 440,307 shares in the company, valued at $54,487,991.25. This represents a 0.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Seamus Mulligan purchased 100,000 shares of the firm's stock in a transaction on Friday, May 9th. The shares were purchased at an average price of $98.26 per share, with a total value of $9,826,000.00. Following the completion of the acquisition, the director now directly owns 100,000 shares of the company's stock, valued at approximately $9,826,000. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold 3,000 shares of company stock valued at $355,925 over the last three months. 4.30% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on JAZZ shares. UBS Group upgraded Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and upped their target price for the stock from $145.00 to $179.00 in a research report on Friday, March 7th. JPMorgan Chase & Co. increased their price objective on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. Truist Financial increased their target price on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a "buy" rating in a report on Thursday, March 6th. Royal Bank Of Canada reduced their target price on Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. Finally, Cantor Fitzgerald downgraded shares of Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and upped their price target for the stock from $140.00 to $150.00 in a research note on Wednesday, February 26th. Two analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $184.00.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.